News

August 25, 2020

POINT Biopharma Further Strengthens Executive Team with Key Clinical and Financial Members

POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, is announcing the appointment of key members to its leadership team — Jessica Jen...

August 4, 2020

Announcing our $20M Series A Financing to Bring Precision Radioligand Therapy to Cancer Patients

POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, has completed a USD $20 Million Series A financing round. Proceeds of the financing ...

June 23, 2020

ITM and POINT Biopharma Sign Two Supply Agreements for No-carrier-added Lutetium-177

ITM Isotopen Technologien München AG (ITM), a biotechnology and radiopharmaceutical group of companies, and POINT Biopharma Inc., a clinical oncology company, announced today that they have signed two supply agreements for the medica...

May 26, 2020

POINT Biopharma to Launch First US Manufacturing Facility in Indiana

POINT Biopharma (POINT) announced plans today to establish its first U.S. manufacturing facility in Indianapolis. “Indiana has established itself as a global leader in life sciences, ranking second in the nation for total exports," Go...

May 24, 2020

POINT Biopharma Announces Manufacturing Leadership and Search for US manufacturing site

POINT Biopharma Inc. today announced the appointment of Todd Hockemeyer as Executive Vice President of US Manufacturing Operations. An industrial engineer, with operations and manufacturing expertise spanning over 25 years, Hockemeyer...